A recent deal between the biopharmaceutical companies GlaxoSmithKline and Novartis may mean more jobs and more attention for the Research Triangle. Plus, the $1.1 billion sale of Furiex pharmaceuticals increases possibilities for investment in the area. Meanwhile, Mooresville's Vestiq Holdings, a much smaller pharmaceutical company, is filing for bankruptcy.
Host Frank Stasio talks with Triangle Business Journal reporter Jason deBruyn.
